Major Depressive Disorder | Effects of Seroquel XR on Sleep Architecture in Patients With Major Depressive Disorder

Major Depressive Disorder research study

What is the primary objective of this study?

In this study, patients with major depressive disorder (MDD) who have insomnia symptom are treated with Seroquel XR in an open-label manner for a 4-week period with repeated measurements of insomnia symptoms and sleep parameters using polysomnography.

Who is eligible to participate?

Patient Inclusion Criteria: - Men and women aged between 20 and 65 - Diagnosis of major depressive disorder as assessed by Structured Clinical Interview for DSM-IV (SCID-IV) - A score of 1 or greater on any of the sleep items (items 4, 5, 6) from the Hamilton Depression Rating Scale (HDRS) - Provision of written informed consent Healthy Control Subject Inclusion Criteria: - Healthy Men and Women aged between 20 and 65 - Provision of written informed consent Exclusion Criteria: - Presence of any major physical or neurological illness (e.g.,head trauma, epilepsy,seizure,stroke,cerebral tumor,multiple sclerosis,cerebrovascular disease, narrow-angle glaucoma, drug hypersensitivity,etc.) - Diagnosis of any Axis I disorder other than major depressive disorder or presence of symptoms requiring hospitalization - Drug abuse in past 3 months - Women who are pregnant,breastfeeding, or planning pregnancy - Contraindications to drugs used in the study (e.g., allergy, intolerance, etc.) - Unstable medical illness or severe abnormality in laboratory test at screening assessment - Increase in blood glucose, lipid, and calcium levels at screening - Low blood pressure at screening assessment - Intelligence quotient below 80 - Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrolment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir - Use of any of the following cytochrome P450 3A4 inducers in the 14 days preceding enrolment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort, and glucocorticoids - Administration of a depot antipsychotic injection within one dosing interval (for the depot) before randomisation - Substance or alcohol dependence at enrolment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM-IV criteria - Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV criteria within 3 months prior to enrolment - Previous enrolment or randomisation of treatment in the present study. - Participation in another drug trial within 4 weeks prior enrolment into this study or longer in accordance with local requirements - Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment - A patient with Diabetes Mellitus - An absolute neutrophil count (ANC) of <= 1.5 x 10^9 per liter - Insomnia from other causes of medical or neurological diseases - Involvement in the planning and conduct of the study

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Major Depressive Disorder

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Quetiapine Fumarate Extended ReleaseDay 1 50mg, Day 2 50mg, Day 3 150mg, Day 4~28 50~150mg (increments and deduction of 50mg are allowed)

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Seroquel XRPatients with MDD receives Seroquel XR.

healthy control

Study Status


Start Date: March 2012

Completed Date: February 2014

Phase: Phase 2

Type: Interventional


Primary Outcome: change from baseline Pittsburgh Quality Index total scores at 4 weeks

Secondary Outcome: change from baseline in sleep architecture measured using polysomnography at 4 weeks

Study sponsors, principal investigator, and references

Principal Investigator: Inkyoon Lyoo, MD, PhD, MMS

Lead Sponsor: Ewha Womans University


More information:

Discuss Seroquel